Virginia C. Drosos, President of Assurex Health, Receives the EY Entrepreneur of the Year 2017 Award in Ohio Valley Region
19 June 2017 - 9:05PM
Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in molecular
diagnostics and personalized medicine, today announced that
Virginia (“Gina”) C. Drosos, president of Assurex Health, a
wholly-owned subsidiary of Myriad Genetics, has received the EY
Entrepreneur of the Year award for health care services in the Ohio
Valley Region. The awards program recognizes entrepreneurs
who excel in innovation, financial performance and personal
commitment to their businesses and communities. Award winners
have built some of the world’s most enduring companies, surpassing
U.S. market performance in terms of revenue growth, job creation
and longevity.
“We congratulate Gina on her outstanding accomplishment.
Her visionary leadership has built Assurex Health into one of the
most successful and fastest growing personalized medicine companies
in history,” said Mark C. Capone, president and CEO of Myriad
Genetics. “Under her leadership, the innovative GeneSight®
test has been used by over 19,000 healthcare professionals to help
improve the lives of more than 500,000 patients suffering from
depression and other mental health disorders.”
Gina joined Assurex Health in 2013. Previously, she
managed a $6 billion dollar global brand portfolio in the consumer
goods and personal care industries at Procter & Gamble for 25
years. She holds a B.S. in Business Administration from The
Terry School, University of Georgia, and an M.B.A. from The Wharton
School, University of Pennsylvania.
About The GeneSight® TestThe GeneSight test
helps healthcare providers make better treatment decisions based on
a person’s genetic makeup. GeneSight testing is based on advanced
CPGx® technology, a patented approach that analyzes variations and
combinations of a person’s genes along with FDA-approved
medications for behavioral health conditions and chronic pain.
Peer-reviewed, published studies have proven its clinical benefits
and substantial healthcare cost savings. More than 19,000
healthcare professionals have used GeneSight with over 500,000
patients. Learn more at www.GeneSight.com.
About Assurex HealthAssurex Health, a
wholly-owned subsidiary of Myriad Genetics, Inc., is an
informatics-based, personalized medicine company providing
treatment decision support to healthcare providers for behavioral
health and chronic pain conditions. Assurex Health is the only
company in the category with multiple peer-reviewed, published
studies that demonstrate the clinical validity and clinical utility
of the GeneSight® test, including its substantial healthcare cost
savings benefit. The Company has grown every quarter and has
expanded internationally through a partnership with Canada’s Centre
for Addiction and Mental Health (CAMH). For more on how Assurex
Health is helping people gain mental wellness, visit
www.AssurexHealth.com.
About Myriad GeneticsMyriad Genetics Inc., is a
leading personalized medicine company dedicated to being a trusted
advisor transforming patient lives worldwide with pioneering
molecular diagnostics. Myriad discovers and commercializes
molecular diagnostic tests that: determine the risk of developing
disease, accurately diagnose disease, assess the risk of disease
progression, and guide treatment decisions across six major medical
specialties where molecular diagnostics can significantly improve
patient care and lower healthcare costs. Myriad is focused on
three strategic imperatives: transitioning and expanding its
hereditary cancer testing markets, diversifying its product
portfolio through the introduction of new products and increasing
the revenue contribution from international markets. For more
information on how Myriad is making a difference, please visit the
Company's website: www.myriad.com.
Myriad, the Myriad logo, BART, BRACAnalysis, Colaris, Colaris
AP, myPath, myRisk, Myriad myRisk, myRisk Hereditary Cancer,
myChoice, myPlan, BRACAnalysis CDx, Tumor BRACAnalysis CDx,
myChoice HRD, EndoPredict, Vectra, GeneSight and Prolaris are
trademarks or registered trademarks of Myriad Genetics, Inc. or its
wholly owned subsidiaries in the United States and foreign
countries. MYGN-F, MYGN-G.
Safe Harbor
Statement This
press release contains “forward-looking statements” within the
meaning of the Private Securities Litigation Reform Act of 1995,
including statements relating to Assurex Health being one most
successful and fasted growing personalized medicine companies in
history; the ability of the GeneSight test to help improve care for
people with depression or other mental health disorders; and the
Company’s strategic directives under the caption “About Myriad
Genetics.” These “forward-looking statements” are based on
management’s current expectations of future events and are subject
to a number of risks and uncertainties that could cause actual
results to differ materially and adversely from those described or
implied in the forward-looking statements. These risks include, but
are not limited to: the risk that sales and profit margins of our
existing molecular diagnostic tests and pharmaceutical and clinical
services may decline or will not continue to increase at historical
rates; risks related to our ability to transition from our existing
product portfolio to our new tests; risks related to changes in the
governmental or private insurers’ reimbursement levels for our
tests or our ability to obtain reimbursement for our new tests at
comparable levels to our existing tests; risks related to increased
competition and the development of new competing tests and
services; the risk that we may be unable to develop or achieve
commercial success for additional molecular diagnostic tests and
pharmaceutical and clinical services in a timely manner, or at all;
the risk that we may not successfully develop new markets for our
molecular diagnostic tests and pharmaceutical and clinical
services, including our ability to successfully generate revenue
outside the United States; the risk that licenses to the technology
underlying our molecular diagnostic tests and pharmaceutical and
clinical services tests and any future tests are terminated or
cannot be maintained on satisfactory terms; risks related to delays
or other problems with operating our laboratory testing facilities;
risks related to public concern over our genetic testing in general
or our tests in particular; risks related to regulatory
requirements or enforcement in the United States and foreign
countries and changes in the structure of the healthcare system or
healthcare payment systems; risks related to our ability to obtain
new corporate collaborations or licenses and acquire new
technologies or businesses on satisfactory terms, if at all; risks
related to our ability to successfully integrate and derive
benefits from any technologies or businesses that we license or
acquire, including but not limited to our acquisition of Assurex,
Sividon and the Clinic; risks related to our projections about the
potential market opportunity for our products; the risk that we or
our licensors may be unable to protect or that third parties will
infringe the proprietary technologies underlying our tests; the
risk of patent-infringement claims or challenges to the validity of
our patents; risks related to changes in intellectual property laws
covering our molecular diagnostic tests and pharmaceutical and
clinical services and patents or enforcement in the United States
and foreign countries, such as the Supreme Court decision in the
lawsuit brought against us by the Association for Molecular
Pathology et al; risks of new, changing and competitive
technologies and regulations in the United States and
internationally; the risk that we may be unable to comply with
financial operating covenants under our credit or lending
agreements; the risk that we will be unable to pay, when due,
amounts due under our credit or lending agreements; and other
factors discussed under the heading “Risk Factors” contained in
Item 1A of our Annual report on Form 10-K for the fiscal year ended
June 30, 2016, which has been filed with the Securities and
Exchange Commission, as well as any updates to those risk factors
filed from time to time in our Quarterly Reports on Form 10-Q or
Current Reports on Form 8-K.
Media Contact:
Ron Rogers
(801) 584-3065
rrogers@myriad.com
Investor Contact:
Scott Gleason
(801) 584-1143
sgleason@myriad.com
Myriad Genetics (NASDAQ:MYGN)
Historical Stock Chart
From Aug 2024 to Sep 2024
Myriad Genetics (NASDAQ:MYGN)
Historical Stock Chart
From Sep 2023 to Sep 2024